What is more, the application of the serotonin reuptake inhibitor improved the impaired hippocampal neurogenesis and memory by enhancing activation of the ILK–Akt–GSK3β axis, suggesting ILK as a promising therapeutic target for AD prevention and treatment [180]. This evidence concerns the gene GSK3B and Alzheimer disease.